Alyeska Investment Group L.P. purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 371,180 shares of the biotechnology company's stock, valued at approximately $53,428,000. Alyeska Investment Group L.P. owned approximately 0.66% of Repligen at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of RGEN. Tidal Investments LLC grew its holdings in Repligen by 142.8% during the 3rd quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company's stock valued at $1,659,000 after buying an additional 6,558 shares in the last quarter. Peapack Gladstone Financial Corp bought a new stake in Repligen during the 3rd quarter worth approximately $296,000. Franklin Resources Inc. lifted its stake in Repligen by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company's stock worth $47,551,000 after purchasing an additional 26,668 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares during the period. Finally, Everence Capital Management Inc. purchased a new position in shares of Repligen during the 4th quarter valued at $294,000. 97.64% of the stock is owned by institutional investors.
Repligen Trading Down 2.0 %
Shares of Repligen stock traded down $2.51 during trading on Friday, reaching $125.34. 217,852 shares of the stock were exchanged, compared to its average volume of 723,531. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.04 billion, a price-to-earnings ratio of -245.76, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The stock's fifty day moving average is $135.66 and its 200 day moving average is $145.46.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. As a group, equities research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Margaret Pax bought 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.20% of the company's stock.
Analyst Ratings Changes
RGEN has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Royal Bank of Canada lowered their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $173.25.
Read Our Latest Stock Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
